By rethinking creative as an interactive educational experience, and not just a promotional message, pharmaceutical brands ...

At Lineage Cell Therapeutics, CEO Brian Culley has been working for many years on allogeneic cell therapies across a range of ...

Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD- (L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer.

The new announcements bring the number of IPOs priced this week to four, coming shortly after South San Francisco ...

"EMA will now review all available data to assess whether this emerging information has an impact on the balance of benefits ...

Acute pancreatitis is linked to the development of gallstones, which are listed as a side effect with GLP-1 drugs. Ahmed said it is not clear at the moment whether the drugs cause the gallstones or if ...

AstraZeneca is already deeply embedded in China's pharma sector, and is hungry for more, pledging $15 billion to an investment programme in the country and signing a mammoth licensing deal with Hong ...

The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...

Tenpoint Therapeutics is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, ...

US digital physical therapy specialist Sword Health has bought its competitor Kaia Health for $285 million, positioning it ...

Traditional cell therapies rely on “clean targets” – antigens that are found on cancer cells but not on healthy cells. Where ...

The South San Francisco start-up is offering 17.6 million shares at a price range of $16 to $18, which would give the company ...